mTOR-inhibiting medicine · Fact sheet
Sirolimus
Also known as rapamycin · Rapamune
Sirolimus is FDA approved for specific transplant and lymphangioleiomyomatosis uses—not to slow aging or extend life. Small healthy-aging trials are exploratory, while approved labeling documents major infection, malignancy, metabolic, lung, wound-healing, and interaction risks.
What is Sirolimus?
Sirolimus is a macrolide medicine that inhibits mTOR, a signaling pathway involved in growth, nutrient sensing, immunity, and cell maintenance.
Rapamycin extends lifespan in several animal models, but translating that finding to healthy humans requires outcomes trials and careful safety testing.
Benefits people look for
mTOR is a central geroscience target, making sirolimus one of the most discussed drug-repurposing candidates in longevity research.
The same immune and growth pathways that make it scientifically interesting also explain why benefits cannot be considered separately from risk.
What the evidence supports
- Small aging trials suggest that controlled research is feasible and have reported selected exploratory signals.
- The PEARL trial did not establish a general longevity benefit and its primary visceral-fat outcome was not significantly improved overall.
All research areas
- Organ-transplant immunosuppression
- Lymphangioleiomyomatosis
- Immune aging and vaccine response
- Physical function and biological-aging measures
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- Approved labeling carries boxed warnings and describes increased susceptibility to infection and possible development of malignancies.
- Other important risks include high cholesterol and triglycerides, impaired wound healing, mouth inflammation, blood-cell changes, lung toxicity, kidney-related concerns, and extensive drug interactions.
- Risk in closely monitored transplant or rare-disease care cannot be assumed acceptable for a healthy person seeking longevity.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Strong human evidence for approved usesEvidence is strong for labeled medical uses, where monitoring and risk management are part of care. Healthy-aging evidence consists of small feasibility and exploratory trials without proof of longer life or prevention of age-related disease.
Selected research to read
Exploratory controlled trial that did not prove longevity or broad healthspan benefit.
Small randomized study focused on feasibility and selected physiological outcomes.
FDA approval & research status
FDA-approved sirolimus products have specific indications, including prevention of organ rejection in selected kidney-transplant patients and treatment of lymphangioleiomyomatosis. Aging and longevity are not approved indications.
Approved uses covered here
- Specific transplant and lymphangioleiomyomatosis uses described in current FDA-approved labeling
FDA approved for non-aging indications
Sirolimus is FDA approved under Rapamune labeling for defined medical uses. Healthy-aging or longevity use remains investigational and should not be folded into the approval.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Whether sirolimus can extend healthy human lifespan
- Whether any aging-related benefit outweighs immune, metabolic, and other harms
- Which biomarkers are meaningful rather than merely responsive
- Long-term outcomes in healthy or near-healthy populations
The takeaway
Sirolimus is not a generic anti-aging supplement. It is a consequential prescription immunosuppressant whose longevity use remains unproven.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA prescribing information: Rapamune
Official indications, boxed warnings, contraindications, adverse reactions, and interactions.
- 2pubmedPEARL randomized trial of sirolimus in healthy aging
Exploratory controlled trial that did not prove longevity or broad healthspan benefit.
- 3pubmedPilot sirolimus study in older adults
Small randomized study focused on feasibility and selected physiological outcomes.